We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Integrated DNA Technologies Launches its First Cancer Panel


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Integrated DNA Technologies Launches its First Cancer Panel"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Integrated DNA Technologies (IDT) is enabling cancer research with its latest next generation sequencing (NGS) product, the xGen® Acute Myeloid Leukemia Cancer Panel v1.0.

Consisting of 11,743 xGen Lockdown® Probes, this cancer panel targets over 260 clinically relevant genes that were found to be mutated in a study of 200 patients with acute myeloid leukemia (AML), and published by The Cancer Genome Atlas consortium.

The AML Cancer Panel is used for enriching the genome for regions of interest before performing NGS. It can, therefore, be used to study disease occurrence and progression, and help with the development of better targeted therapies.

Target enrichment enables users to focus their sequencing efforts on specific regions of the genome, providing a cost-effective and reliable alternative to whole genome sequencing, making NGS more accessible to researchers.

By including only relevant xGen Lockdown Probes, the AML Cancer Panel enables high coverage of targeted regions, with minimal GC bias.

As cancer is a genetic disease driven by both heritable and somatic mutations, NGS technologies can significantly improve its detection, management, and treatment.

DNA from a patient could be enriched for these AML-related genes using capture panels such as the xGen AML Cancer Panel and sequenced to identify mutated genes. Subsequently, the patient would receive therapy specific to their cancer profile.

Periodic sequencing of these genes would allow monitoring of disease progression for both research and clinical purposes. As such, more tailored therapies can be developed and a personalized treatment regimen can be implemented.

Ibrahim Jivanjee, Product Manager for NGS at IDT, commented, “We have invested a significant amount of resources into the development of our xGen product line, and are delighted to see such success from these products already. The launch of our first cancer panel has been a significant milestone, with early collaborators demonstrating its potential for use in patient diagnosis and monitoring.”

He continued, “With next gen sequencing becoming an increasingly prominent technique within cancer diagnosis and personalized medicine, IDT, with its leading position in oligonucleotide technology will continue to be at the forefront of developments in this rapidly advancing field.”

Advertisement